Alercell Inc.

Alercell, Inc., a Montana company, is a molecular diagnostics company specialized in oncology diagnostic. In business since 2020, need capital to grow to the next step.
Alercell, Inc., a Montana company, is a molecular diagnostics company pioneering novel oncology diagnostics tests to discover, develop, and commercialize solutions for clinical unmet needs. Alercell is a true innovator, disruptor, and leader in the field of preventative oncology. The company was founded with the aim of providing more accurate and timely diagnostic tools for cancer patients worldwide. Alercell's mission is to make a difference in the fight against cancer by providing innovative and accurate diagnostic solutions that improve patient outcomes. At stage 1 of cancer and Leukemia, 95% of patients walk free of cancer within an average of 18 months without the grueling treatments. At stage 2+ the percentage decreased exponentially, thus, being able to detect malignancy prior to clinical symptoms or at a very early stage is critical. This is what we are working on at Alercell.

In response to the unprecedented challenges posed by the novel coronavirus pandemic that emerged in early 2020, we extended our enduring commitment to reducing infectious disease mortality in the U.S. through early detection. Specifically, we acquired and brought to market several COVID-19 antibody tests, including rapid kits and laboratory-based tests. The company generated up to $4.5 million in revenue. As the pandemic subsided, we reverted to our primary core activities, rededicating ourselves to our vital mission in the field of oncology diagnostics and ultimately therapeutics.

In 2023, Alercell marked a historic milestone with the launch of LENA Q51®, the world's first Leukemia diagnostic test capable of analyzing up to 51 genetic mutations. Leukemia, a life-threatening blood disorder, involves approximately 200 genetic variations within the human genome. Until then, the most advanced competing test, still in the research and development phase, could only detect up to 14 gene mutations. Remarkably, prior to 2023, the standard Leukemia tests could only examine two gene mutations. Lena Q51 January 2023, Alercell, Inc. marked a historic milestone with the launch of LENA Q51®, the world's first Leukemia diagnostic test capable of analyzing up to 51 genetic mutations. Leukemia, a life-threatening blood disorder, involves approximately 200 genetic variations within the human genome. Until then, the most advanced competing test, still in the research and development phase, could only detect up to 14 gene mutations. Remarkably, prior to 2023, the standard Leukemia tests could only examine two gene mutations. Lena Q51 now needs to go through extensive FDA clinical trials required for full commercialization. 

In 2024, we just unveil a revolutionary test Lena S1® based on methylated genes to detect small cell lung cancer. Lung cancer is a deadly disease, and the level of fatalities is high du=e to very late detection. Our test allows very early detection. It is a life saver for a lot of patients. We are now in the phase of speaking with a few cancer centers for human testing in the USA and we need to go through the costly FDA clinical trials process.

We know that the technology unveiled in the Lena S1® methylation test can be expanded to Leukemia. We are in conversation with a few large players to dive in using Artificial Intelligence. We know how to adapt Machine Learning and other more complex models to this type of application; one member of our team has written an algorithm already being used in AI in several health centers and currently being evaluated by large AI conglomerates.

We have a strong management consisting of medical doctors, biotech specialists and businessmen

 

We are seeking $500,000 to allow us to start commercialization and position for the FDA clinical trials we need. It is a first step to prove our concept.